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Abstract
Streptococcus agalactiae, or group B streptococcus (GBS), remains the leading cause of neonatal sepsis and meningitis, as early-onset or
late-onset diseases (EOD, LOD). Where consensus guidelines to detect and treat intrapartum women with GBS colonization have been
widely adopted, incidence of neonatal EOD has dramatically declined. In response to both successful impacts on the incidence of GBS-
EOD and analyses of missed opportunities, the ﬁrst American guidelines for prevention issued in the 1990s have since been adapted in
several stages to improve their efﬁcacy. In some countries in Europe, nationwide guidelines, whether screening-based or risk-based, for
the prevention of neonatal GBS diseases have also been issued and adopted, with the expected impact on incidence of GBS-EOD. In
spite of universal screening, in spite of the great progress that has been made, GBS-EOD continues to occur and the GBS burden
remains a signiﬁcant public health issue. Continuous efforts to improve screening for GBS status continue to be important and may be
able to take advantage of new rapid diagnostic technologies. The current screening-based strategy for prevention is highly effective but
imperfect. Given the challenges, limitations and potential complications of maternal intrapartum prophylaxis, a new approach is still
needed. Maternal immunization against GBS is an attractive alternative for the prevention of not only neonatal diseases but also still-
births and maternal diseases. Vaccines against GBS may become the most effective and sustainable long-term preventive strategy.
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Introduction
In the 1970s, Streptococcus agalactiae, also referred to as
Lanceﬁeld group B streptococcus (GBS), emerged abruptly
as an important pathogen causing invasive bacterial infections,
sepsis, pneumonia and meningitis in human neonates during
the ﬁrst week of life [1]. Since that time, GBS has remained
the leading infectious cause of neonatal morbidity and mor-
tality in industrialized countries, affecting 0.5–3 newborns in
every 1000 live births [2–8]. In less-developed countries, the
incidence of GBS neonatal disease also varies widely: 0.17
per 1000 live births in India to three per 1000 live births in
sub-Saharan Africa [9–12].
Two distinct clinical syndromes among infants became
apparent: early-onset disease (EOD) presenting within the
ﬁrst week of life, and late-onset disease (LOD) affecting
infants between 1 week and 3 months old [1–4,13,14].
Because many babies with GBS-EOD disease are already
septicaemic at birth, limiting the opportunity for timely inter-
ventions, disease prevention rather than treatment is the
focus of attempts to reduce neonatal GBS infections and the
burden of the disease. Today, with the implementation of
speciﬁc policies, the overall incidence of GBS-EOD has pro-
gressively declined [3,8,15–17]. However, prevention of
EOD is still the subject of controversy, and despite consider-
able efforts and economic resources spent on prevention of
GBS-EOD, cases continue to occur [2,4,5,13,15,18–20].
ª2011 The Author
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2011.03576.x
Group B streptococcal diseases are not restricted to new-
borns. They are also common in pregnant women and have
been recognized as an ever-growing cause of severe invasive
infections in non-pregnant adults, particularly older adults
and immunocompromised patients [1,3,7,13,21]. In women
during pregnancy or the postpartum period, genital tract col-
onization with GBS is usually asymptomatic, but GBS clinical
manifestations include urinary tract infections, chorio-
amnionitis, endometritis, wound infections associated with
caesarean delivery or episiotomy, puerperal sepsis and, occa-
sionally, meningitis, septic thrombophlebitis, or other serious
complications [13]. Infections with GBS probably cause 15–
25% of puerperal fever with or without bacteraemia [1,3].
Women colonized with GBS during pregnancy are at
increased risk of stillbirths and premature delivery [13].
GBS, the Bacteria and Colonization
Group B streptococci are Gram-positive encapsulated bacte-
ria usually subdivided according to their type speciﬁc capsu-
lar polysaccharides (CPS) into ten antigenically unique
serotypes (Ia, Ib, II–IX) [1]. This capsule represents one of
the major virulence factors [14]. Among GBS, serotype III
strains are responsible for a considerable percentage of EOD
and for the majority of LOD [20,22]. Furthermore, a highly
virulent clone of GBS serotype III, GBS ST-17, is reported in
several studies as the main sequence type causing neonatal
invasive disease and as being responsible for almost all cases
of meningitis [20].
Group B streptococci remain fully susceptible to penicillin
as well as to most b-lactams, and penicillin remains the ﬁrst-
choice antibiotic to prevent GBS-EOD and to treat GBS dis-
ease. However, recently identiﬁed very rare isolates with
decreased susceptibility to penicillin have been reported in
Japan and the USA [23]. A point mutation in the GBS pbp2x
gene conferring this decrease in susceptibility was identiﬁed
[23]. Their clinical signiﬁcance is unclear, and clinicians can
conﬁdently continue to use penicillin and other b-lactams for
intrapartum antibioprophylaxis (IAP) and treatment of GBS
infections. Of more concern is the ﬁnding that, over the last
two decades, resistance to macrolides and clindamycin
among invasive isolates of GBS has increased from <5% to
common resistance of 20–30% [17,24,25]. Different known
mechanisms account for acquired resistance to macrolides.
The most prevalent of these is based on the alteration of
the target-binding site, a ribosomal modiﬁcation mediated by
erythromycin ribosome methylase encoded by erm genes.
The presence of an Erm methylase confers resistance to
erythromycin and inducible or constitutive resistance to lin-
cosamides and streptogramin B, the so-called MLSB pheno-
type. Another mechanism, involving increased drug efﬂux, is
conferred by the mef gene; the presence of a Mef pump only
affects 14-membered and 15-membered macrolides, the
M phenotype. These resistances are worrying, and continuing
surveillance of susceptibility patterns is therefore warranted.
The gastrointestinal tract is the natural reservoir for GBS
and is likely the source for vaginal colonization [1,3]. Many
adults, up to 30%, are commonly colonized with GBS in the
gastrointestinal and genital tract but remain asymptomatic.
Vaginal colonization is unusual in childhood but becomes
more common in late adolescence [2]. Among pregnant
women, GBS carriage rate in the vaginal and rectal micro-
biota ranges from 10% to 37% and is similar in developing
and developed countries [16,18,22,26]. Large variations in
colonization rates can be observed and correlated with body
sites sampled, microbiological procedures performed and
populations studied. The site chosen for culture is critical
[1]: the distal vagina yields GBS more frequently than the
cervix, and collecting both vaginal and rectal swabs results in
optimal detection of carriers. Colonization with GBS can be
transient, intermittent or persistent [3,16] and, as it is com-
monly asymptomatic, bacteriological screening must be
performed to identify carriers. Irrespective of preventive
strategy for GBS-EOD, the GBS colonization rate among
pregnant women has remained steady over time, and no
marked change has been observed in the distribution of
serotypes [16].
GBS Neonatal Disease
Early and late onset diseases
Among cases of GBS-EOD, which typically occur within the
ﬁrst 6 days of life, the greatest number present with signs of
systemic infection at birth or within the ﬁrst 24 h: fulminant
pneumonia or sepsis or, less commonly, meningitis
[1,3,14,27]. Without prompt therapy, rapid clinical deteriora-
tion typically characterizes EOD. Despite intensive support-
ive care and diagnostic and therapeutic advances, these
infections remain associated with high mortality and morbid-
ity. GBS early-onset infection is vertically transmitted and is
characteristically related to maternal carriage of GBS in the
genital tract, with vertical transmission occurring immediately
before or during labour and delivery. About 30–70% of neo-
nates born to GBS-colonized mothers become transiently
colonized by their mother’s organism. Most of them remain
asymptomatic, but among these infants 1–3% develop a
severe disease [1,3,7,16,19,27]. They can become colonized
or infected in utero or contaminated with GBS upon passage
CMI Melin Neonatal group B streptococcal disease 1295
ª2011 The Author
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1294–1303
through the birth canal during parturition. A direct relation-
ship exists between the density of GBS vaginal carriage at
the onset of labour or rupture of membranes and the risk of
vertical transmission and likelihood of serious neonatal dis-
ease [16].
The second peak of disease incidence, LOD, occurs
around 1 month after birth in infants with most infections
evident between the seventh day and the third month, after
which infections are rare [1–4,13,14].
Infants with GBS-LOD usually present bacteraemia and
often (nearly one-quarter of cases) develop meningitis
[1,20,28]. Cellulitis and osteoarticular infections may occur
but are relatively rare [1,28]. In contrast to EOD, late-onset
infection is not always acquired from the mother. Horizontal
transmission during the perinatal period may occur from
mother to infant or from hospital or community sources.
Another reported source of infection is breastfeeding
[29–32].
Burden of the disease
Before the introduction of any preventive strategy, the bur-
den of GBS-EOD was high: 70–80% of neonatal cases and
20–30% of LOD [1,19]. The natural incidence of GBS-EOD,
before preventive intervention, ranged from 0.5 to 4 or even
more cases per 1000 live births with substantial geographical
variations. In Europe, reported incidence varies from country
to country: 0.2–4 per 1000 live births in Eastern Europe
[33], 0.3–2 in Western Europe [33], 1.9 in the Netherlands
[33], 0.76–2 in Scandinavia [33], 0.57–2 in southern Europe
[33], 0.5–2 in Spain [8] and 2–3 in Belgium [6,22]. Wide vari-
ations in incidence could be correlated with differences in
women’s GBS carriage rate, with differences of ethnic or
racial susceptibility to GBS infection, with usual location for
delivery in or outside hospital, with systematic diagnostic
approaches and with differences in virulence among the pre-
valent GBS strains. In less-developed countries, with a similar
exposure to maternal GBS as in industrialized countries, the
incidence of neonatal GBS disease is apparently lower, 0.17
per 1000 live births in India for example [9]. This could
reﬂect a combination of several factors, including insufﬁcient
surveillance, the prevalence of less virulent strains, higher
levels of transplacentally acquired protective antibody in
serum or unrecognized causes of early neonatal or prema-
ture deaths and stillbirths, resulting in inaccurate recording
of the incidence of GBS-EOD [3,34]. In the USA, after the
widespread implementation of preventive strategies, the inci-
dence decreased dramatically from 1.7 cases per 1000 live
births in 1993 to < 0.4 cases per 1000 live births in 2008
[3–5,13,15,17]. In European countries where a preventive
strategy was adopted, an important drop of the incidence of
GBS-EOD was also observed as is well demonstrated by
Spain: from 2.4 cases per 1000 live births in 1996 to 0.45 in
2008 [8]. Globally, over the same 20-year period, the inci-
dence of GBS-LOD has remained relatively steady with 0.4
cases per 1000 live births [4,5,7,13,16,17,19,35].
The initial reported case fatality rate associated with EOD
dropped from 50% or higher to around 4–10%
[13,17,19,28,30,36]. However, in Norway, the case fatality
rate of 6.5% in the period 1996–2005 increased to 16.3% in
2006–2007. This phenomenon is worrying because it could
be related to an increase of resistance to erythromycin and
clindamycin, which might indicate the emergence of more
virulent GBS strains [37]. However, in all countries, among
preterm affected neonates, the case fatality rate remains sub-
stantially higher than among full-term infants—up to eight
times higher with decreasing gestational age [3,16,36].
Improved outcomes for both clinical syndromes, EOD and
LOD, are probably the result of better recognition and
prompt treatment of symptomatic babies and of advances in
neonatal medical care.
In addition, the burden of GBS-EOD extends beyond neo-
natal illness and death, including such long-term impairments
as vision or hearing loss and mental retardation. Among sur-
vivors of GBS meningitis, approximately 50% of the children
have some deﬁcit, and up to 30% have severe neurological
sequelae [3,13,16].
It is noteworthy that reported incidences are based solely
on cases proven by culture of GBS from a normally sterile
site such as blood or cerebrospinal ﬂuid. Therefore, as sug-
gested by some studies, reported incidences of GBS diseases
are likely to underestimate the true burden, which is proba-
bly one- to three-fold higher [19,38]. Systematic cultures are
not always performed, and there can be false-negative cul-
tures related to the very small volume of blood inoculated,
to previous antimicrobial treatment or to antibiotics adminis-
tered to the mother during labour.
Group B streptococci are also a well-recognized cause of
spontaneous abortions and stillbirths, but the burden attrib-
utable to GBS is difﬁcult to quantify [13]. The relation
between GBS and preterm delivery is regularly observed but
is complex, making establishing causality difﬁcult.
Pathogenesis of GBS-EOD
The process of neonatal infection by GBS is complex and
multifactorial. Host factors play a central role in determining
the pathogenic potential of GBS, but bacterial virulence fac-
tors also assist GBS in their progression within the host.
The ﬁrst stage in the pathogenesis of GBS-EOD is the
establishment of vaginal colonization in the pregnant woman
including adherence to vaginal epithelial cells and resistance
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to mucosal immune defences. To gain access to the fetus,
GBS may ascend into the amniotic cavity. Bacterial prolifera-
tion allows GBS to colonize the skin or mucous membranes
of the fetus or to enter the fetal lung through aspiration of
infected amniotic ﬂuid [14]. After birth, GBS must success-
fully replicate within the alveoli of the neonate, adhere to
respiratory epithelium, and avoid clearance by pulmonary
macrophages. Pneumonia with lung cell injury is characteris-
tic of GBS-EOD, and may be mediated in part by the cyto-
toxic properties of GBS b-haemolysin and the inﬂux of host
neutrophils [14]. The invasion by GBS of the pulmonary epi-
thelial and endothelial cells may allow GBS to enter the
bloodstream causing septicaemia. This bloodstream dissemi-
nation may lead to meningitis and osteomyelitis. This disease
progression indicates that GBS has to evade the host’s natu-
ral immune defences to adhere, to invade and to transcytose
several cell barriers.
One of the major virulence factors is CPS expressed by
GBS, which helps bacterial evasion by interfering with their
ingestion by phagocytes [1,14]. For efﬁcient phagocytosis,
GBS need opsonization by speciﬁc antibodies or comple-
ment. Both of these may be present in neonatal serum but
in small amounts, more especially in preterm newborns.
Another important virulence factor, a prerequisite for GBS
invasiveness and disease, is the capacity of GBS for adher-
ence, their ability to attach to the vascular endothelium and
epithelium, particularly of the vaginal tissue and chorionic
membranes as well as the neonatal lungs [39]. Pili appear to
play a key role in a ﬁrm and intimate speciﬁc adherence of
GBS to the host’s epithelial cells and to promote transepi-
thelial migration [40,41]. Other identiﬁed factors produced
by GBS interfere with host defences, such as the production
of C5a peptidase that inactivates human C5a, a neutrophil
chemoattractant produced during complement activation
[14]. Furthermore, cell wall components trigger the host’s
inﬂammatory response inducing a sepsis syndrome [14]. On
occasion, GBS can cross intact placental membranes, which
may lead to severely ill neonates at time of delivery or even
to stillbirth [14,42].
Risk factors for GBS-EOD
Whereas the mother’s vaginal colonization with GBS during
labour is a prerequisite for EOD, additional maternal and
obstetric factors described below affect the risk of EOD
[1,2,15,20]. Listed ﬁrst are the ‘classical ﬁve’ identiﬁed in the
ﬁrst surveillance studies conducted in North America and
still acknowledged worldwide: (i) GBS bacteriuria at any time
during the current pregnancy probably indicates a heavy
vaginal colonization [2]. (ii) Chorioamnionitis, intrapartum
maternal fever, a marker of chorioamnionitis, and (iii) rup-
ture of membranes more than 18 h before delivery may sig-
nal a prolonged infant exposure to GBS before delivery
[2,16,43]. (iv) Preterm labour and delivery before 37 weeks
of gestation are related to an incomplete transfer of maternal
antibodies resulting in low levels of anti-capsular antibodies
homologous to the maternal GBS colonizing strain. Preterm
infants are at three-fold to 30-fold greater risk of developing
EOD compared with full-term infants, with the highest risk at
lower gestational ages [3,44]. Whereas preterm newborns
have a much greater risk of GBS-EOD, about 75% of cases
arise among full-term infants [5,44]. (v) A previous sibling with
invasive GBS disease may indicate a low level of speciﬁc GBS
antibodies in the mother, a risk factor that could persist in
subsequent pregnancies [16,45]. However, a substantial pro-
portion, up to 50%, of GBS-EOD develops in neonates born
to mothers who did not demonstrate any of the ‘classical
ﬁve’ risk factors [5,22,45]. Other risk factors that have been
reported are: black race [15,17], young maternal age [3,9],
and certain obstetric procedures such as the use of intra-
uterine fetal monitoring devices or performing ﬁve or more
vaginal examinations during labour [13,16,46].
Evolution of Guidelines for Prevention of
GBS-EOD
Intrapartum antibioprophylaxis
During the past two decades, major initiatives have been
proposed to prevent GBS-EOD. These were mainly pro-
moted in the USA and further adapted and translated into
national guidelines in some European countries. In the late
1980s, clinical trials demonstrated that GBS-EOD might be
prevented by administering antibacterial prophylaxis during
labour and delivery to women who are colonized by GBS
[3,27]. Selective intravenous antimicrobial treatment with b-
lactams turned out to be the most practical and effective
mode of prevention. The main goal is to reduce or eliminate
transmission of GBS to the infant. [1,3,5,7,16].
Despite the availability of an effective intervention, chal-
lenges and controversy among obstetricians and paediatri-
cians focused on how best to identify candidates for IAP.
The simplest and cheapest strategy, universal IAP for all
deliveries, was not considered advisable because of unneces-
sary exposure to antibiotics. Different options, either based
on the presence of risk factors associated with increased risk
of GBS-EOD or on GBS-positive late antenatal cultures,
were then recommended to identify women at risk of deliv-
ering a GBS-infected infant [2]. However, each strategy pre-
sented drawbacks [13]. For the screening-based option,
problems included: the question of when women should be
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screened given the transience of GBS colonization, the
absence of a rapid test that could be performed in labour,
logistics and strategies for reaching women without prenatal
care and communication of results. The risk-based option
was less complex, but women with risk factors are not all
colonized with GBS and many neonates with GBS disease
have mothers who had not shown these risk factors
[9,22,28]. Although neither option was optimal or properly
implemented, surveillance studies documented an up to 65%
decline in GBS-EOD, and, during the same period, invasive
GBS disease among pregnant women declined by 20% [4,13].
The IAP had no effect on GBS-LOD incidence, which
remains unchanged [7].
In 2002, a large retrospective cohort study compared the
effectiveness of both approaches in the real-life setting: uni-
versal GBS antenatal screening at 35–37 weeks of gestation
was found to be the most effective option and was >50%
more effective [4]. Therefore, in 2002, the Centers for Dis-
ease Control and Prevention (CDC), referring to these ﬁnd-
ings, released revised guidelines recommending late-antenatal
GBS screening at 35–37 weeks of gestation for all women
and IAP for women with GBS colonization, the risk-based
approach being reserved for women who arrive at labour
with unknown colonization status [5]. As expected, an active
population-based surveillance in the USA showed a further
27% decrease in incidence of GBS-EOD from 0.47 to 0.34
cases per 1000 live births after the guidelines were issued
[16,17]. However, among the remaining burden of disease,
there may be preventable cases [9,15,17,20]. Van Dyke et al.
[15] identiﬁed potential areas for improvement: (i) to
increase the percentage of IAP administered to women who
deliver preterm with unknown colonization status, (ii) to
improve management of women who are allergic to penicillin
by giving the appropriate antibiotic based on antimicrobial
susceptibility results and (iii) to improve the accuracy of GBS
prenatal screening. In 2010, the CDC issued a new revision
of the recommended guidelines. There was no major change,
but they speciﬁcally addressed improvement of laboratory
screening methods for GBS, management of women with
preterm labour or preterm premature rupture of mem-
branes, updated prophylaxis regimens for women allergic to
penicillin and revised the algorithm for management of new-
borns at risk of GBS-EOD.
Similarly, since the end of the 1990s, several European
countries have recommended and offered culture-based test-
ing for maternal GBS colonization including Spain (1998 and
2003), France (2001), Belgium (2003), Germany (1996,
2008), and Switzerland (2007) [22,47–50]. For some other
countries, cost-effectiveness studies of a universal screening-
based approach in their epidemiological background were
not convincing, and the risk-based option is recommended in
the UK and in the Netherlands for instance [51,52]. In other
European countries, no guideline exists at all, for example, in
Bulgaria and Denmark [33].
Vaccines
Maternal opsonizing antibodies are transferred actively to
babies during the third trimester of pregnancy, and anti-CPS
IgG concentrations in infants are inversely correlated with
their risk of developing GBS-EOD and -LOD [44]. There-
fore, vaccination represents a practical, attractive alternative,
targeting women of childbearing age to subsequently protect
neonates against GBS infection. It is the most promising
approach because GBS vaccines might prevent a broad
scope of GBS-associated diseases such as EOD, LOD, spon-
taneous abortion, stillbirth and maternal bacteraemia
[1,3,16,17,19,20,34,44,53,54]. Furthermore, vaccines devel-
oped for the prevention of perinatal infections might also
protect at-risk non-pregnant adults, increasing the target
population for an efﬁcacious vaccine.
Initially, development of vaccines targeted serotype CPS.
The ﬁrst challenge was to improve their immunogenicity.
Clinical trials have demonstrated safety and immunogenicity
of different CPS–protein or tetanus toxoid-conjugated vac-
cines prepared with types Ia, Ib, II, III and V [17,53,55]. But
the development of vaccines with global relevance has been
hampered by changes in the distribution of GBS serotypes of
strains causing diseases over time and in different parts of
the world. A multivalent vaccine to cover against the more
prevalent serotypes suitable for European populations might
not be suitable for Asian or African populations [34]. There-
fore, to overcome type-speciﬁcity, new developments target
vaccines based on conserved surface antigenic proteins, such
as Sip protein located at the cell surface of all GBS
[20,34,56] and on immunogenic proteins from GBS pili [54].
These new protein candidates for vaccine were discovered
through modern technologies such as proteomics and geno-
mic sequencing [34,54]. A pilus-based GBS vaccine is appeal-
ing and could become a globally relevant reality. The idea is
to elicit immune responses that counteract the essential bio-
logical role of pili, such as to promote GBS adhesion to host
tissue and GBS transepithelial migration. A combination of
three pilus components conferred protection against 94% of
contemporary GBS strains circulating in the USA and Italy
[54]. In an era of IAP, designing clinical trials is not feasible
in many countries. An immune surrogate marker of protec-
tion, such as the level of maternal speciﬁc antibody, which
correlates with resistance to GBS disease in infants, could be
used to replace efﬁcacy trials. A study, conducted by the
DEVANI project (Design of a Vaccine Against Neonatal
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Infections, a European Commission Seventh Framework Pro-
gramme, http://www.devaniproject.org) is currently underway
in Europe to identify such a surrogate marker.
Vaccination of women before or during pregnancy is likely
to be the most effective, sustainable and cost-effective
approach of all and avoids the drawbacks around screening
and antibiotic use. However, administration of a new vaccine
to pregnant women is worrisome because of the fear of
risks of birth defects. Hence, the most viable approach is
through vaccination before pregnancy. Adolescents may be
the most appropriate target group with a boosting schedule
to assure protection to infants of mothers of all ages, but
maternal vaccination might be easier than adolescents’ vacci-
nation because of their increased contact with the healthcare
system for prenatal care and might be feasible in developing
countries. Although tests of GBS vaccines have yielded very
promising results, licensed vaccines are not yet available.
Outline of Screening-based Guidelines
The main goal of the screening-based strategies is to reduce
or eliminate transmission of GBS to the infant by giving anti-
biotics to GBS-colonized women during delivery. Guidelines
recommended by the CDC [17] or by several European
countries [22,47–50] are similar in their main features and
are based around IAP and universal antenatal screening cul-
ture for GBS colonization in pregnant women [22,47]. The
risk-based approach is no longer an acceptable alternative
except for circumstances in which screening results are not
available before delivery. The screening-based guidelines are
addressed to obstetric- and neonatal-care practitioners, labo-
ratories and labour and delivery facilities. For ideal imple-
mentation, all the tools and means that could improve
collaboration and communication between these different
medical staff must be used. Another key for success is their
integration into the daily practice of the management of
women and neonates during pregnancy and at delivery, with-
out too great an expense or excess of work.
Indications for IAP
Indications and non-indications to identify pregnant women
candidates for IAP are summarized in Fig. 1. For the women
admitted with signs and symptoms of threatened preterm
delivery, speciﬁc revised algorithms for screening and man-
agement are provided in the CDC’s guidelines for 2010 [17].
Chemoprophylaxis regimen
Regimens for IAP and alternatives for penicillin-allergic
women are summarized in Table 1. Penicillin, for its narrower
spectrum of antimicrobial activity, its resultant decreased
potential for selection of resistant organisms and its likely
minor effect on enteric bacterial species, is preferred to
ampicillin as the ﬁrst choice for IAP, but the efﬁcacy of both
agents administered intravenously for the prevention of GBS-
EOD was has been reported in clinical studies [27]. With the
recommended dosages of penicillin and ampicillin, rapidly
therapeutic levels are reached in the fetal blood and amniotic
Vagino-rectal GBS screening culture at 35–37 weeks’ gestation for     
all pregnant women 
  Intrapartum prophylaxis not indicated 
* If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active 
against GBS should replace the GBS prophylaxis.
** Rupture of amniotic membrane 
$
 NAAT: Nucleic acid amplification test if available 
- Not done 
- Incomplete or   
unknown GBS result
Yes
  Unless patient had a previous infant with GBS invasive disease 
or GBS bacteriuria during the current pregnancy 
or delivery  occurs <37 weeks’ gestation 
Intrapartum prophylaxis indicated 
 No
   ≥ 1 maternal risk factor:
       - Intrapartum fever ≥38°C * 
       - ROM  ≥ 18 h ** 
Intrapartum NAAT positive 
for GBS 
or
$
GBS
negative 
GBS
positive 
Yes
FIG. 1. Indication for intrapartum antibiopro-
phylaxis to prevent early-onset group B strep-
tococcal (GBS) disease under a universal
prenatal strategy. Adapted from revised guide-
lines from CDC, 2010 [17] and Belgian guide-
lines, 2003 [22].
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ﬂuid. It has been shown that penicillin or ampicillin adminis-
tered at least 4 h before delivery was highly effective at pre-
venting vertical transmission of GBS and EOD [1,17,27,57],
but shorter duration might still provide some protection
[17]. Regarding the other agents recommended as alternatives
for penicillin-allergic women, no controlled trials have
demonstrated their efﬁcacy. Cefazolin has very similar anti-
microbial spectrum, pharmacokinetics and pharmacodynamics
to penicillin, but data for clindamycin, erythromycin and
vancomycin are limited. Following reports of sub-therapeutic
levels in fetal circulation and amniotic ﬂuid, erythromycin is
no longer recommended for IAP [17,22,58].
Screening – specimen collection and processing
The aim of GBS screening is to predict the vaginal GBS colo-
nization status at time of delivery. Methods that maximize
the likelihood of GBS recovery are required, and speciﬁc
media are needed. Critical factors that inﬂuence the accuracy
of detecting GBS maternal colonization include sampled ana-
tomic sites, timing in pregnancy, transport condition of swabs
and culture procedures. In addition, failure to culture GBS
may be caused by maternal factors, such as use of oral anti-
biotics or a variety of feminine hygiene products before
specimen collection.
Table 2 presents a summary of the procedure for speci-
men collection for GBS screening and of an improved
method for culture.
Antimicrobial susceptibility testing
To select appropriately the antibiotic prophylaxis for penicil-
lin allergic women at high risk of anaphylaxis, antimicrobial
susceptibility testing of GBS isolates is essential. In addition,
speciﬁc methods must be used to detect inducible clinda-
mycin resistance, which can occur in isolates that are
apparently susceptible. The D-zone testing is recommended
to identify those isolates [59].
Diverse conditions, management of neonate
Further details, other conditions and clinical management of
infants at risk for GBS-EOD are given and proposed in the
full text of the various nationwide guidelines [17,22,47–50].
Critical Factors, Limitations and
Improvements of IAP
Several aspects of antenatal and perinatal clinical practice,
including inaccurate GBS screening, lack of communication of
GBS-screening results, improper implementation of IAP and
microbiological factors including antibiotic resistance, may all
contribute to ongoing disease. As shown in several studies
and by Van Dyke et al., GBS-EOD occur in full-term infants
born to mothers screened negative for GBS colonization and
in preterm infants born to mothers who were not screened
[15,20,36]. Between 60% and 80% of cases occur among
infants born to women with a negative antenatal GBS screen
[15,36]. As GBS carriage is highly variable, the predictive val-
ues of GBS antenatal cultures are not always good predictors
of the maternal GBS status at presentation for delivery.
Whether these negative cultures were false-negative results
or the mothers acquired GBS in the interval between the
screening culture and the time of delivery is unknown. Fur-
TABLE 1. Recommended regimens for intrapartum antibi-
otic prophylaxis for prevention of early onset group B strep-
tococcal disease.
For patient not allergic to penicillin
Penicillin G: 5 million units intravenous (IV) initial dose, then 2.5–3.0 million
units every 4 h until delivery
Acceptable alternative
Ampicillin: 2 g IV initial dose, then 1 g IV every 4 h until delivery
For patient allergic to penicillin
And no history of anaphylaxis or angio-oedema or respiratory distress or
urticaria after receiving penicillin or a cephalosporin
Cefazolin: 2 g IV initial dose, then 1 g IV every 8 h until delivery
With a history of anaphylaxis or angio-oedema or respiratory distress or
urticaria after receiving penicillin or a cephalosporin
And group B streptococcus isolate susceptible to clindamycina
Clindamycin: 900 mg IV every 8 h until delivery
Or group B streptococcus isolate resistant to clindamycin or if unknown
susceptibility result
Vancomycin: 1 g IV every 12 h until delivery
Adapted from revised guidelines from CDC [17], 2010 and Belgian guidelines,
2003 [22]
aIf the isolate is resistant to erythromycin and apparently susceptible to clinda-
mycin: testing for inducible clindamycin resistance must be performed, and if
negative, clindamycin can be used.
TABLE 2. Obstetrician’s procedure for collecting specimens
for culture of group B streptococcus (GBS) at 35–37 weeks
of gestation and laboratory procedure for processing speci-
mens.
When At 35–37 weeks of gestation
Who All pregnant women at the time of pregnancya
Which site Lower vagina (vaginal introitus) and rectum
(through anal sphincter)
Material One (or two) swab(s) for collection of both
sites placed in non-nutritive transport medium
(e.g. Amies or Stuart’s)
Storage and Transport Transfer specimen to laboratory within the day
If any delay, refrigerate specimen (2–8C) for no
longer than 48 h
Requesting form Clearly request culture for ‘GBS screening’.
Culture processing Enrichment culture in selective broth (e.g. Lim
or TransVag) further subcultured on to solid
selective differential medium (e.g. Granada or
speciﬁc chromogenic media).
If positive, test isolate for clindamycin susceptibility
by using test to detect either constitutive or
inducible resistance (D-zone test)
Adapted from Belgian guidelines 2003 [22]
aUnless: patient had a previous infant with GBS invasive disease or patient had
GBS bacteriuria during the current pregnancy or delivery occurs <37 weeks’
gestation
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thermore, negative GBS screens may provide a false sense of
reassurance to obstetric providers. Just as there are women
who acquire GBS in the interval between screening and
delivery, so there are women who are no longer colonized
by the time of labour and will unnecessarily receive IAP.
Improving microbiological procedures for screening should
contribute to increasing predictive values and to further
decreasing the incidence of GBS-EOD disease. Use of appro-
priate transport media, limitation to <48 h for the time
between collection and processing of the specimen, system-
atic inoculation in selective enrichment broth further sub-cul-
tured on selective differential media, such as Granada agar
and chromogenic media, represent the key elements to
improve GBS screening cultures [17,22,47].
Rapid diagnostic tests
Several studies have conﬁrmed the expected beneﬁt of using
a reliable, highly sensitive, easy to perform, rapid test. A
strategy based upon a rapid test performed intrapartum
should be cost-effective leading to the prevention of more
GBS-EOD cases while reducing the number of women
unnecessarily given IAP. To allow timely and targeted IAP to
the larger number of GBS-positive screened women, turn-
around time of such a test, from ward to bench to bed,
should not exceed 1 h. Such a test should be available 24 h a
day, 7 days a week. An accurate rapid test for GBS coloniza-
tion proved difﬁcult to develop. During the last two decades,
rapid antigenic and hybridization-based tests were produced.
Although they have good speciﬁcities, they tend to have dis-
appointing performance with low sensitivities, which only
increase with heavy colonization; hence a negative test can-
not rule out GBS colonization [60].
PCR-based tests
Advances in PCR and ﬂuorescence labelling technologies
have provided new detection platforms for bacterial identiﬁ-
cation [61]. Recent data suggest that available real-time PCR-
based tests (or Nucleic Acid Ampliﬁcation Test (NAAT)) can
equal or surpass the sensitivity of antenatal culture at 35–
37 weeks of gestation and compare favourably with standard
culture methods for the detection of GBS colonization at
presentation for delivery [17,18,60–63]. Therefore, the com-
mercialization of rapid detection of GBS through real-time
PCR offers the potential for GBS detection among women
without prenatal care or among those in whom no antenatal
culture was collected. Based on these developments, the
Xpert GBS (Cepheid), cleared by the Food and Drug
Administration in 2006, a real-time PCR assay can yield
results in 30–75 min and is characterized by an extremely
low workload. It is simple enough for even inexperienced
technicians to perform. However, use of this relatively new
and more expensive technology is not currently widespread
among European hospitals and must still be assessed for its
use in the screening-based strategy. Haberland et al. [64]
cost analysis suggests that the beneﬁts of rapid simple NAAT
exceed their costs. Further studies using rapid NAAT per-
formed shortly before delivery in real-life conditions, are
needed to identify targeted populations and settings where
the test will be most useful, and, to assess their utility for
GBS disease prevention.
An expected improvement of these tests is the combined
detection of GBS with the detection of markers for resis-
tance to clindamycin, to guide the appropriate IAP for peni-
cillin-allergic women at high risk of anaphylaxis.
Unintended Consequences in the Era of
IAP
With the successful implementation of IAP strategies, con-
cerns arise regarding the increased use of antimicrobials
among pregnant women in labour resulting in the exposure
of a large number of women and infants to possible adverse
effects without beneﬁt [65]. Might there be adverse effects
such as maternal anaphylaxis, death and increased incidence
of Gram-negative or drug-resistant neonatal sepsis? Even
though limited studies have been controversial, global surveil-
lances have not conﬁrmed these fears and are not of sufﬁ-
cient magnitude to outweigh the beneﬁts of IAP to prevent
GBS-EOD [4,8,15–17,19,66,67]. As reported by Tanaka et al.
[68], infants’ antibiotic exposure through maternal IAP might
inﬂuence the development of neonatal intestinal microbiota.
Continued surveillance of neonatal sepsis is needed to moni-
tor changes in neonatal pathogens, antibiotic resistance pro-
ﬁles and antibiotic use.
Another cause of anxiety was how IAP might affect the
clinical presentation of GBS-EOD and could prevention
efforts impair the ability to diagnose the disease? Several
studies have found that the pattern of GBS-EOD was not
affected by exposure to IAP [36].
Conclusion
In 2011, neonatal GBS diseases remain a global public health
concern. IAP for the prevention of GBS-EOD has been suc-
cessful with over 70% reduction in GBS-EOD; however,
despite preventive strategies cases still occur. The strategy
was not expected to prevent all cases and there are chal-
lenges and limitations to this preventive approach.
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The best strategy for European countries is still a matter
of debate and IAP was not widely recommended. To adopt
the best preventive strategy, we ﬁrst need better data
assessing more accurately the true burden of GBS diseases
in the different countries.
A new generation of vaccines is under development and is
very promising. But, licensure of effective global vaccines to
prevent GBS diseases in both neonates and adults is still
awaited.
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